Fierce Biotech September 10, 2024
Genesis Therapeutics’ shiny AI drug discovery platform GEMS is catching on, having now caught the eye of Gilead Sciences.
In Genesis’ third big pharma collaboration, Gilead has agreed to pay its new partner $35 million up front for AI-based drug discovery work on three undisclosed targets. Further, Gilead “will have an option to nominate additional targets for a predetermined per-target fee,” according to a Sept. 10 press release.
Under the deal, Gilead secures development and commercialization rights to any compounds that arise from a result of the discovery efforts. Genesis would be in line for milestone payments and potential tiered royalties on those prospects.
“Many promising protein targets have a paucity of relevant training data, which makes it difficult to...
Today's Sponsors
Today's Sponsor